Journal of Clinical Oncology最新文献

{"title":"Mosunetuzumab plus polatuzumab vedotin in transplant-ineligible refractory/relapsed large B-cell lymphoma: primary results of the phase 3 SUNMO trial.","authors":"Lihua E Budde,Huilai Zhang,Won-Seog Kim,Dai Maruyama,Eduardo M Rego,Lalita Norasetthada,Huangming Hong,Muhit Ozcan,Young-Woo Jeon,Danielle Leão Cordeiro de Farias,Laura Maria Fogliatto,Astrid Pavlovsky,Hideki Goto,Adam J Olszewski,Nikesh Shah,Bei Hu,Shen Yin,Hao Wu,Iris To,Wahib S Ead,Joan Ashby,Martin Janousek,Song Pham,Jue Wang,Antonia Kwan,Connie L Batlevi,Michael C Wei,Jason Westin","doi":"10.1200/jco-25-01957","DOIUrl":"https://doi.org/10.1200/jco-25-01957","url":null,"abstract":"PURPOSEPrognosis for patients with refractory/relapsed large B-cell lymphoma (LBCL) considered ineligible for curative-intent therapy is poor. The combination of mosunetuzumab, a T-cell-engaging bispecific antibody, and polatuzumab vedotin, an antibody-drug conjugate, (Mosun-Pola), represents a novel fixed-duration outpatient therapy.METHODSIn the phase 3 SUNMO trial, patients with refractory/relapsed LBCL who were ineligible for autologous stem cell transplant were randomized (2:1) to receive Mosun-Pola or rituximab, gemcitabine, and oxaliplatin (R-GemOx). Dual primary endpoints were centrally-assessed overall response rate and progression-free survival. Overall survival was a key secondary endpoint.RESULTSA total of 208 patients were randomized to receive Mosun-Pola (n=138) or R-GemOx (n=70). At a median follow-up of 23.2 months, the primary analysis of SUNMO demonstrated that the median progression-free survival was significantly longer with Mosun-Pola than with R-GemOx(11.5 months [95% confidence interval (CI), 5.6-18] vs 3.8 months [95% CI, 2.9-4.1]; hazard ratio for progression or death, 0.41 [95% CI, 0.3-0.6]; P<0.0001). Overall response rate was significantly greater with Mosun-Pola versus R-GemOx (70% vs 40%; P<0.0001), with a complete response rate of 51% and 24%, respectively. In the Mosun-Pola group, the rate of grade ≥2 cytokine release syndrome and usage of tocilizumab occurred in less than 5% of patients, and patient-reported outcomes were improved compared with R-GemOx.CONCLUSIONMosun-Pola demonstrated superior efficacy verus R-GemOx, with significant improvements in both overall response rate and progression-free survival, and infrequent cytokine release syndrome events with a manageable safety profile.(Funded by F. Hoffmann-La Roche Ltd; ClinicalTrials.gov, NCT05171647).","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":"75 1","pages":"101200JCO2501957"},"PeriodicalIF":45.3,"publicationDate":"2025-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145209088","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bringing Trustworthy Artificial Intelligence to the Clinical Forefront at JCO: A Guide for Studies Testing Artificial Intelligence Models.","authors":"Ravi B Parikh,Alexia Iasonos,Andrew Ko,Jeremy Warner,Kathy Miller,Jonathan W Friedberg","doi":"10.1200/jco-25-01939","DOIUrl":"https://doi.org/10.1200/jco-25-01939","url":null,"abstract":"","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":"75 1","pages":"JCO2501939"},"PeriodicalIF":45.3,"publicationDate":"2025-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145209121","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum: Prospective Study of Supplemental Screening With Contrast-Enhanced Mammography in Women With Elevated Risk of Breast Cancer: Results of the Prevalence Round.","authors":"Bhavika K Patel, Molly B Carnahan, Donald Northfelt, Karen Anderson, Gina L Mazza, Victor J Pizzitola, Marina E Giurescu, Roxanne Lorans, William G Eversman, Richard E Sharpe, Laura K Harper, Heidi Apsey, Patricia Cronin, Juliana Kling, Brenda Ernst, Jennifer Palmieri, Jessica Fraker, Lida Mina, Felipe Batalini, Barbara Pockaj","doi":"10.1200/JCO-25-01993","DOIUrl":"10.1200/JCO-25-01993","url":null,"abstract":"","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":" ","pages":"3140"},"PeriodicalIF":41.9,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144955809","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Phase II Study of ¹⁷⁷Lu-DOTATATE for Progressive Metastatic Pheochromocytomas and Paragangliomas: Interim Analysis of Efficacy, Safety, and Biomarkers.","authors":"Frank I Lin, Jaydira Del Rivero, Jorge A Carrasquillo, Abhishek Jha, Joy Zou, Inna Shamis, Sara Talvacchio, Baris Turkbey, Erich P Huang, Joanna Shih, Joanna Klubo-Gwiezdzinska, Esther Mena, Liza Lindenberg, Yating Teng, Freddy E Escorcia, Clara Chen, Peter Herscovitch, Corina Millo, Peter L Choyke, Karel Pacak","doi":"10.1200/JCO-25-00791","DOIUrl":"10.1200/JCO-25-00791","url":null,"abstract":"<p><strong>Purpose: </strong>¹⁷⁷Lu-DOTA(0)-Tyr(3)-octreotate (¹⁷⁷Lu-DOTATATE) is a somatostatin receptor (SSTR)-targeting radiopharmaceutical that shows promise for treating metastatic pheochromocytomas/paragangliomas (PPGLs), a rare SSTR-expressing tumor.</p><p><strong>Methods: </strong>In the first stage of this two-stage Simon phase II trial, 36 PPGL patients with RECIST 1.1 progression within 12 months were prospectively recruited into two genetic cohorts (succinate dehydrogenase [<i>SDHx</i>]-mutated <i>v</i> apparent sporadic, 18 per cohort) and treated with four cycles of ¹⁷⁷Lu-DOTATATE. The primary end point was progression-free survival (PFS) rate at 6 months (from initiation of treatment). Secondary end points included safety, overall survival (OS), response rate, imaging/serum biomarkers, and antihypertensive medication reduction. Computed tomography/magnetic resonance imaging (CT/MRIs) and positron emission tomography (PET)-CTs (⁶⁸Ga-DOTATATE and ¹⁸F-labeled fluorodeoxyglucose) were obtained after two and four cycles, then every 3 (CT/MRIs) to 6 months (PET/CTs). Patients with systolic blood pressure (SBP) > 200 mmHg despite medical management were treated in the intensive care unit (ICU).</p><p><strong>Results: </strong>Six-month PFS rate for all patients was 0.861 (95% CI, 0.755 to 0.982), which was significantly lower (<i>P</i> = .009) for <i>SDHx</i> at 0.72 (95% CI, 0.542 to 0.962) versus sporadic at 1.00 (95% CI, 1.0 to 1.0). Median PFS was 19.9 months (12.9 months <i>SDHx v</i> 24.3 months sporadic) and median OS was 51.7 months (31.2 months <i>SDHx v</i> not reached in sporadic). Best response was achieved on average 11.0 months after completing ¹⁷⁷Lu-DOTATATE. A 17% incidence of grade 3+ catecholamine release syndrome (CRS) was noted, which may benefit from preemptive ICU admission. Plasma chromogranin A and normetanephrine were the best tumor-marker surrogates and correlated well with changes in RECIST sum and total tumor lesion uptake on serial ⁶⁸Ga-DOTATATE PET-CT scans.</p><p><strong>Conclusion: </strong>¹⁷⁷Lu-DOTATATE demonstrated effectiveness and acceptable safety profile for progressive, metastatic PPGL. CRS may occur but can be mitigated through pretreatment with antihypertensives, and, when appropriate, intensified monitoring in the ICU with intravenous antihypertensives.</p>","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":" ","pages":"3102-3112"},"PeriodicalIF":41.9,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12367064/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144882947","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Brown Paper Bags.","authors":"Stephanie L Graff","doi":"10.1200/JCO-25-01474","DOIUrl":"10.1200/JCO-25-01474","url":null,"abstract":"<p><p>Have you ever received a gift from a patient? Tell us about the experience-was it an exchange of kindness, gratitude, humor, or perhaps shock or confusion? Read as @DrSGraff shares what she has found in Brown Paper Bags.</p>","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":" ","pages":"3132-3133"},"PeriodicalIF":41.9,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144955801","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is There a Role for Mifamurtide in Nonmetastatic High-Grade Osteosarcoma? Results From the Italian Sarcoma Group (ISG/OS-2) and Spanish Sarcoma Group (GEIS-33) Trials.","authors":"Emanuela Palmerini, Cristina Meazza, Angela Tamburini, Catalina Márquez-Vega, Gianni Bisogno, Franca Fagioli, Virginia Ferraresi, Giuseppe Maria Milano, Luca Coccoli, Alba Rubio-San-Simón, Oscar Gallego, María Esther Llinares Riestra, Carla Manzitti, Jaume Mora, Mᵃ Ángeles Vaz-Salgado, Roberto Luksch, Cristina Mata, Michela Pierini, Elisa Carretta, Marilena Cesari, Anna Paioli, Andrea Marrari, Katia Scotlandi, Massimo Serra, Sebastian Dorin Asaftei, Marco Gambarotti, Piero Picci, Stefano Ferrari, Claudia Valverde, Toni Ibrahim, Javier Martín Broto","doi":"10.1200/JCO-25-00210","DOIUrl":"10.1200/JCO-25-00210","url":null,"abstract":"<p><strong>Purpose: </strong>Outcome of patients with localized osteosarcoma is challenging. The role of mifamurtide is still a matter of debate. Two prospective trials were carried out in Italy (ISG/OS-2) and Spain (GEIS-33) with mifamurtide in ABCB1/P-glycoprotein (Pgp)-positive patients.</p><p><strong>Patients and methods: </strong>Patients age ≤40 years with localized extremity high-grade osteosarcoma were eligible. Analysis of Pgp expression from diagnostic biopsy was centralized. Patients received two cycles of preoperative methotrexate, doxorubicin, and cisplatinum (MAP) before surgery. Postoperatively, in case of Pgp overexpression (Pgp-positive), mifamurtide was added, combined with doxorubicin (one cycle) and four consecutive cycles of high-dose ifosfamide (HDIFO) for patients with poor histologic response, or with MAP in case of good response. Patients who were Pgp-negative received MAP postoperatively. We present the merged analysis of ISG/OS-2 and GEIS-33 trial, an observational study with same inclusion criteria and treatment of ISG/OS-2. The primary endpoint was 5-year event-free survival (EFS) according to the use of mifamurtide. Secondary endpoint was overall survival (OS).</p><p><strong>Results: </strong>From March 2013 to April 2018, 398 patients were analyzed. The median age was 14 years (range, 4-40), male/female: 238/160 (1.48/1.0); 211 of 398 (53%) tumors were Pgp-positive, and 204 of 398 (51.3%) patients received mifamurtide. With a median follow-up of 70 months (IQR, 49-90 months), the 5-year EFS and OS were 65.2% (95% CI, 60.1 to 69.8) and 74.8% (95% CI, 69.8 to 79.0), respectively, with superior EFS for patients undergoing mifamurtide and chemotherapy as compared with EFS of patients undergoing chemotherapy alone (5-year EFS 71.4% <i>v</i> 58.3%; <i>P</i> = .0139) not confirmed at multivariable analysis (<i>P</i> = .0593).</p><p><strong>Conclusion: </strong>In this merged analysis with a risk-adapted strategy for nonmetastatic osteosarcoma, the group with unfavorable prognoses, identified by Pgp expression, performed well when mifamurtide, combined with HDIFO in case of poor response, was administered after surgery.</p>","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":" ","pages":"3113-3122"},"PeriodicalIF":41.9,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12456199/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144873345","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identifying Patients With Low Relapse Rate Despite High-Risk Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: Development and Validation of a Clinicopathologic Assay.","authors":"François-Clément Bidard, Grégoire Gessain, Thomas Bachelot, Lucie Frechin, Anne Vincent-Salomon, Damien Drubay, Jérôme Lemonnier, Thomas Walter, Frédérique Penault-Llorca, Anne-Laure Martin, Catherine Gaudin, Antoine Bichat, Farah Sassi, Sylvain Berlemont, Mariana Chavez-MacGregor, Hope S Rugo, Cécile Badoual, Barbara Pistilli, Joana Ribeiro, Antonio Di Meglio, Magali Lacroix-Triki, Ines Vaz Luis, Marvin Lerousseau, Fabrice André","doi":"10.1200/JCO-25-00742","DOIUrl":"10.1200/JCO-25-00742","url":null,"abstract":"<p><strong>Purpose: </strong>Escalation of adjuvant systemic therapies (eg, with cyclin-dependent kinase 4 and 6 inhibitors) is now indicated for patients with clinically defined high-risk estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) early breast cancer, although it is unclear which will benefit from additional therapies. We developed and validated a prognostic clinicopathologic assay identifying a subpopulation of high-risk patients with good prognosis after standard adjuvant therapies, who may safely forgo treatment escalation.</p><p><strong>Methods: </strong>We trained a Cox proportional-hazards model that integrates clinicopathologic variables with features derived from digitized hematoxylin-and-eosin-stained resection slides from a retrospective data set. The model assigns each patient to a <i>low-risk</i> or <i>not low-risk</i> group, reflecting their predicted risk of recurrence. Blind validation was successively performed on high-risk patients from the prospective trials CANTO (ClinicalTrials.gov identifier: NCT01993498) and UNIRAD (ClinicalTrials.gov identifier: NCT01805271).</p><p><strong>Results: </strong>Built on data from 6,164 patients with ER+/HER2- early-stage breast cancer, this assay integrates four clinicopathologic variables, and 10 slide-derived features capturing tumor architecture, microenvironment, and proliferation. In the combined CANTO and UNIRAD trials (n = 633), 95.4% of the <i>low-risk</i> patients remained free of distant recurrence and death from breast cancer at 9 years, compared with 76.8% for the <i>not low-risk</i> group. Distant recurrence-free interval (subdistribution hazard ratio [HR], 0.21 [95% CI, 0.09 to 0.52]; <i>P</i> < .001), invasive disease-free survival (HR, 0.31 [95% CI, 0.16 to 0.60]; <i>P</i> < .001), and overall survival (HR, 0.35 [95% CI, 0.13 to 0.97]; <i>P</i> = .044) were all statistically significant. Multivariate analyses showed that the assay provided predictive information beyond clinicopathologic variables. Analytical validation showed robustness to data variability.</p><p><strong>Conclusion: </strong>The assay demonstrated robust performance in identifying a core group of patients with high-risk ER+/HER2- breast cancer for whom additional adjuvant treatment may be futile.</p>","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":" ","pages":"3090-3101"},"PeriodicalIF":41.9,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12456196/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144955806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"US Food and Drug Administration Approval Summary: Inavolisib With Palbociclib and Fulvestrant for Endocrine-Resistant, <i>PIK3CA</i>-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, Locally Advanced or Metastatic Breast Cancer.","authors":"Suparna Wedam, Preeti Narayan, Haley Gittleman, Joyce Cheng, Vishal Bhatnagar, Hairat Sabit, Lauren S L Price, Nam Atiqur Rahman, Haw-Jyh Chiu, Nikolett Biel, Tiffany Ricks, Mallorie Fiero, Shenghui Tang, Christy Osgood, William Pierce, Richard Pazdur, Paul G Kluetz, Laleh Amiri-Kordestani","doi":"10.1200/JCO-25-00663","DOIUrl":"10.1200/JCO-25-00663","url":null,"abstract":"<p><strong>Purpose: </strong>The US Food and Drug Administration (FDA) approved inavolisib with palbociclib and fulvestrant for adults with endocrine-resistant, <i>PIK3CA</i>-mutated, hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer (MBC), as detected by an FDA-approved test, FoundationOne Liquid CDx assay, after recurrence on or after completing adjuvant endocrine therapy.</p><p><strong>Patients and methods: </strong>Approval was based on INAVO120, a randomized, double-blind, placebo-controlled trial in 325 patients with endocrine-resistant, <i>PIK3CA</i>-mutated, hormone receptor-positive, HER2-negative, locally advanced or MBC. Patients were randomly assigned (1:1) to either inavolisib (n = 161) or placebo (n = 164) in combination with palbociclib and fulvestrant.</p><p><strong>Results: </strong>INAVO120 met its primary end point of progression-free survival (PFS) by investigator assessment, with a median PFS of 15.0 months for inavolisib + palbociclib + fulvestrant versus 7.3 months for placebo + palbociclib + fulvestrant (hazard ratio [HR], 0.43 [95% CI, 0.32 to 0.59]; <i>P</i> < .0001). The objective response rate was 58% (95% CI, 50 to 66) versus 25% (95% CI, 19 to 32). The median duration of response was 18.4 months (95% CI, 10.4 to 22.2) versus 9.6 months (95% CI, 7.4 to 16.6). Interim analysis of overall survival did not reach statistical significance but was supportive of the overall benefit-risk assessment with a HR of 0.64 (95% CI, 0.43 to 0.97). Consistent with the PI3Kα inhibitor class, common adverse reactions noted with inavolisib included hyperglycemia, stomatitis, diarrhea, and rash.</p><p><strong>Conclusion: </strong>The approval of inavolisib with palbociclib plus fulvestrant was based on a statistically significant and clinically meaningful improvement in PFS observed in the INAVO120 trial. Before this approval, there were no specific therapies approved by the FDA for the first-line treatment of patients with endocrine-resistant, hormone receptor-positive advanced or MBC.</p>","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":" ","pages":"3123-3131"},"PeriodicalIF":41.9,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144955847","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Inotuzumab Ozogamicin Then Blinatumomab for Older Adults With Newly Diagnosed B-Cell ALL: Alliance Study A041703 Cohort 1 Results.","authors":"Matthew J Wieduwilt,Jun Yin,Oudom Kour,Rebecca Teske,Wendy Stock,Carolin Escherich,Jun Yang,Zhenhua Li,Kenneth Byrd,Kimberley Doucette,James Mangan,Scott Hall,Alice S Mims,Katarzyna Jamieson,Shira N Dinner,Ali W Bseiso,Giorgia Giordano,Caner Saygin,Geoffrey L Uy,Mark R Litzow,Richard M Stone","doi":"10.1200/jco-25-00307","DOIUrl":"https://doi.org/10.1200/jco-25-00307","url":null,"abstract":"PURPOSEOlder patients with ALL receiving conventional chemotherapy have poor survival due to toxic death and relapse. We hypothesized that a chemotherapy-free, targeted regimen using the anti-CD22 antibody-calicheamicin conjugate inotuzumab ozogamicin followed by the bispecific anti-CD19/CD3 T-cell engager blinatumomab would reduce toxic death and yield high rates of prolonged remission and survival.METHODSEligible patients were age 60 years and older with untreated, Philadelphia chromosome (Ph)-negative, CD22-positive, B-cell ALL. Patients received up to two cycles of inotuzumab ozogamicin followed by four or five cycles of blinatumomab with intrathecal methotrexate CNS prophylaxis. The primary end point was 1-year event-free survival (EFS).RESULTSThe 33 eligible patients had a median age of 71 years (range, 60-84) and a median CD22 expression of 92% (range, 21%-100%). Eight (24%) had previous chemotherapy or radiation for other cancers, six for multiple myeloma. The composite complete remission rate was 85% after two cycles of inotuzumab ozogamicin and 97% by the end of two cycles of blinatumomab. At a median follow-up of 30 months, the 1-year EFS and overall survival were 75% (95% CI, 61 to 92) and 85% (95% CI, 73 to 98), respectively. EFS was shorter with lower CD22 expression or detectable measurable residual disease at any time point.CONCLUSIONInotuzumab ozogamicin then blinatumomab without maintenance chemotherapy in older patients with untreated, Ph-negative, CD22-positive, B-cell ALL yields a high remission rate and excellent EFS. Given the lack of standard, safe, and effective therapies in this population, the regimen should be considered a standard treatment option.","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":"102 1","pages":"JCO2500307"},"PeriodicalIF":45.3,"publicationDate":"2025-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145194760","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Looking for the Best Allogeneic Donor and the BMT CTN 1702 Study: Noli Tempus Perdere.","authors":"Alessandro Rambaldi","doi":"10.1200/jco-25-01884","DOIUrl":"https://doi.org/10.1200/jco-25-01884","url":null,"abstract":"","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":"28 1","pages":"JCO2501884"},"PeriodicalIF":45.3,"publicationDate":"2025-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145194759","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}